11-06-06

Attorney Docket No. 55325-8167.US06

Express Mail Label No. EV 326 984 441 US

PATENT

NOV 0 3 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICATION OF: Zalipsky et al.

APPLICATION No.: 10/714,085

FILED: November 14, 203

FOR: METHOD FOR TREATING MULTI-DRUG

RESISTANT TUMORS

EXAMINER: Kishore, G.

ART UNIT: 1615

CONF. No: 9528

Supplemental Information Disclosure Statement Within Three Months of Application Filing or Before First Action – 37 C.F.R. § 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. <u>Timing of Submission</u>

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last (37 C.F.R. § 1.97(b)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- Copies of references 1-7 are issued patent(s) and published application(s) and are not included (see C.F.R. § 1.98(a)(2)(i)).
- ☐ Copies of references 8-24 are enclosed.

Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior

art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5.	Patent Term Ad	justment (37	C.F.R. §	1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted, Perkins Coie LLP

Date: 11-3-66

Judy M. Mohr

Registration No. 38,563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

COMPLETE IF KNOWN 10/714,085 **Application Number** INFORMATION DISCLOSURE Confirmation Number 9528 **ŞTATEMENT BY APPLICANT** November 14, 2003 Filing Date Form PTO-1449 (Modified) First Named Inventor Zalipsky et al. Group Art Unit 1615 Examiner Name To be Assigned Sheet of 2 Attomey Docket No. 55325-8167.US06

444					U.S.	PATENT DOCUMENTS	·		
Examiner Initials*	Cit	e		ion I Code known)		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Line Where Relevant Passa or Relevant Figures App	iges
	1.	6,18	30,095	B1	Gre	eenwald et al.	1/01		
	2.	. 6,34	12,244		Zal	ipsky, Samuel	1/02		
	3.	. 6,36	65,179		Zal	ipsky <i>et al</i> .	4/02		
	4.	. 6,60)5,299		Zal	ipsky, Samuel	8/03		
	5.	6,63	38,500	B1	EI-	Tayar Nabil <i>et al</i> .	10/03		
	6.	. 6,84	19,270		Zal	ipsky, Samuel	2/05		
	7.	. 200	4/0213579	A1	Zal	ipsky <i>et al</i> .	10/04		
				FC	DREI	GN PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Fo Office	oreign Patent or Appl	Kind	Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т
	8.	EP	EP 0 317 95	,		Senter	5/89		
	9.	EP	EP 0 898 96	8		Maeda, Hiroshi	3/99		
	10.	PCT	WO00/6448	3		Alza Corporation	11/00		
	11.	PCT	WO00/6448	4		Alza Corporation	11/00		
	12.	PCT	WO01/2662	9		Alza Corporation	4/01		
	13.	PCT	WO02/2626	5		Schering Corporation	4/02		
	14.	PCT	WO03/0534	09		Alza Corporation	7/03		
	15.	PCT	WO04/1104	97		Alza Corporation	12/04		
	<u> </u>	<u> </u>	OTHER PR	IOR A	RT-N	ON PATENT LITERATURE	OCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.			Т				
	16.	Asai e	Asai et al., Biol. Pharm. Bull., <u>21</u> (7):766-771 (1998).						
	17.	17. Briddell <i>et al.</i> , <i>Blood</i> , <u>102(11)</u> :163b-164b (1999).							

EXAMINER		DATE CONSIDERED		
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

Sheet

COMPLETE IF KNOWN		
Application Number	10/714,085	
Confirmation Number	9528	
Filing Date	November 14, 2003	
First Named Inventor	Zalipsky et al.	
Group Art Unit	1615	
Examiner Name	To be Assigned	
Attorney Docket No.	55325-8167.US06	

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	Т	
	18.	Database Dissertation Abstracts [Online] Proquest Info & Learning; Woghiren, Clement O. et al.: "Synthesis, Characterization and Conjugation of a Novel Protected Thiol-Polyethylene Glycol: A New Activated Polymer for Reversible Protein Modification (IL-2)" Dialog Accession No. 01367093; Dissertation Abstracts 55(03-B), 1994, page 866		
	19.	Johnson <i>et al.</i> , <i>Chemistry and Biology</i> , <u>4</u> (12):939-950 (1997).		
	20.	Kratz et al., J. Med. Chemistry, <u>45</u> (12):5523-5533 (2002).		
	21.	Malik et al., Experimental Hematology, 28(7, Suppl. 1):106, Abstract No. 237 (2000).		
	22.	Thorpe et al., Cancer Res., <u>47</u> (12):5924-5931 (1987).		
	23.	Vaage et al., International Journal of Cancer, 80(1):134-137 (1999)		
	24.	Worrell et al., Anticancer Drug Design, <u>1</u> (12):179-188 (1986).		

EXAMINER		DATE CONSIDERED		
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			